A real-world study on the impact of infection load on mortality in multiple myeloma patients in Finland

被引:0
|
作者
Anttalainen, Anna [1 ]
Havula, Essi [1 ]
Kysenius, Kai [1 ]
Toppila, Iiro [1 ]
Miettinen, Tatu [1 ,2 ]
Lassenius, Mariann [1 ]
Silvennoinen, Raija [3 ,4 ]
Partanen, Anu [5 ]
Putkonen, Mervi [6 ]
机构
[1] Medaffcon Oy, Espoo, Finland
[2] Takeda Oy, Helsinki, Finland
[3] Univ Helsinki, Dept Hematol, Helsinki, Finland
[4] Helsinki Univ Hosp, Comprehens Canc Ctr, Helsinki, Finland
[5] Kuopio Univ Hosp, Dept Med, Kuopio, Finland
[6] Turku Univ Hosp, Dept Hematol, Turku, Finland
关键词
Multiple myeloma; Real-world evidence (RWE); Hematology; Oncology; Infection; Autologous stem cell transplant (ASCT); LENALIDOMIDE; DIAGNOSIS; RISK;
D O I
10.1007/s00277-024-06101-3
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Infections are a clinically significant cause of mortality in multiple myeloma (MM) patients. The high number of infections in MM patients is due to the immunosuppressive effects of the disease itself as well as treatment-related immunosuppression. In this real-world evidence (RWE) study, we used several nationwide healthcare registries of Finland to investigate the effect of infection load on mortality in MM patients during 1997-2021. The highest number of infections was recorded during the first year after MM diagnosis. In patients who received allogenic or autologous stem cell transplantation (ASCT), the number of infections during the first two years post diagnosis was significantly higher than in those treated without ASCT. When compared to their age-, sex-, and region-matched controls, MM patients accrued more infections during the year prior to diagnosis. Intriguingly, patients under 70 years old had significantly more infections already 3 years before diagnosis when compared to their matched controls. Prior to MM diagnosis, the relative proportion of streptococcal septicaemia and pneumonia due to Streptococcus pneumoniae increased the most. Of note, even one recorded infection prior to diagnosis was associated with significantly shorter median overall survival. Importantly, Cox proportional hazard models show that recorded infections both before and after diagnosis increase the independent risk of mortality in MM patients.
引用
收藏
页数:13
相关论文
共 50 条
  • [1] Impact of the Availability of Novel Drugs on Overall Survival of Multiple Myeloma Patients: A Real-World Study
    Arcuri, Leonardo Javier
    Silva, Cinthya Correa
    Ovigli, Danielle
    Helman, Ricardo
    Kerbauy, Mariana
    Hamerschlak, Nelson
    BLOOD, 2020, 136
  • [2] Early mortality in elderly patients undergoing treatment for multiple myeloma in real-world practice
    Xia, Jun
    Wang, Lingling
    Zhou, Xin
    Wang, Jing
    Wang, Huan
    Guo, Hongfeng
    JOURNAL OF INTERNATIONAL MEDICAL RESEARCH, 2018, 46 (06) : 2230 - 2237
  • [3] Real-World Retrospective Study of 46 Patients with Macrofocal Multiple Myeloma (MFMM)
    Yan, Wenqiang
    Fan, Huishou
    Xu, Jingyu
    Liu, Jiahui
    Du, Chenxing
    Deng, Shuhui
    Sui, Weiwei
    Xu, Yan
    Qiu, Lugui
    An, Gang
    BLOOD, 2021, 138 : 3765 - +
  • [4] Risk factors and causes of early mortality in patients with newly diagnosed multiple myeloma in a "real-world" study: experiences of the Polish Myeloma Group
    Charlinski, Grzegorz
    Tyczynska, Agata
    Malecki, Bartosz
    Fornagiel, Szymon
    Barchnicka, Agnieszka
    Kolkowska, Agnieszka
    Kopinska, Anna
    Usnarska-Zubkiewicz, Lidia
    Robak, Pawel
    Waszczuk-Gajda, Anna
    Krzystanski, Mateusz
    Jurczyszyn, Artur
    POLISH ARCHIVES OF INTERNAL MEDICINE-POLSKIE ARCHIWUM MEDYCYNY WEWNETRZNEJ, 2021, 131 (06): : 527 - 534
  • [5] The real-world outcomes of multiple myeloma patients treated with daratumumab
    Szabo, Agoston Gyula
    Klausen, Tobias Wirenfeldt
    Levring, Mette Boegh
    Preiss, Birgitte
    Helleberg, Carsten
    Breinholt, Marie Fredslund
    Hermansen, Emil
    Gjerdrum, Lise Mette Rahbek
    Bonlokke, Soren Thorgaard
    Nielsen, Katrine
    Kjeldsen, Eigil
    Iversen, Katrine Fladeland
    Teodorescu, Elena Manuela
    Dokhi, Marveh
    Kurt, Eva
    Strandholdt, Casper
    Andersen, Mette Klarskov
    Vangsted, Annette Juul
    PLOS ONE, 2021, 16 (10):
  • [6] The Efficacy of Roxadustat in Multiple Myeloma Patients with Renal Insufficiency and Anemia: A Real-World Study
    Li, Shuchan
    Han, Xiaoyan
    Zheng, Gaofeng
    He, Jingsong
    Wu, Wenjun
    Yang, Yang
    Chen, Qingxiao
    He, Donghua
    Dong, Mengmeng
    Wang, Jinuo
    Li, Yi
    Yang, Li
    Cai, Zhen
    BLOOD, 2023, 142
  • [7] Stalled CARS. Examining the Real-World Impact of Waiting for CART in Patients with Multiple Myeloma
    Weise, Michael
    Mushtag, Muhammad Umair
    Atrash, Shebli
    Abdallah, Al-Ola
    Mcguirk, Joseph P.
    Lutfi, Forat
    Skikne, Barry
    Ahmed, Nausheen
    Mahmoudjafari, Zahra
    BLOOD, 2024, 144 : 6937 - 6938
  • [8] A real-world study of belantamab mafodotin in a heavily pretreated population of multiple myeloma patients
    Bird, Sarah
    Bishop, Ellouise
    Panopoulou, Katerina
    Saso, Radovan
    Mir, Farheen
    Stern, Simon
    Kaiser, Martin
    Boyd, Kevin
    Pawlyn, Charlotte
    BRITISH JOURNAL OF HAEMATOLOGY, 2023, 201 : 60 - 61
  • [9] Real-world treatment patterns and outcomes in lenalidomide refractory multiple myeloma patients in Europe: a real-world survey
    Martinez-Lopez, Joaquin
    Mendes, Joao
    Luke, Emily
    Kluth, Caspian
    Salmon, Phoebe
    Bailey, Abigail
    Ribbands, Amanda
    Gay, Francesca
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S198 - S199
  • [10] Incidence of corneal adverse events in patients with multiple myeloma and their clinical and economic impact: A real-world retrospective cohort study
    Wang, Feng
    Sansbury, Leah
    Ferrante, Shannon
    Maiese, Eric M.
    Willson, Jenny
    Chen, Chi-Chang
    Nunna, Sasikiran
    Sun, Kainan
    Kleinman, David M.
    JOURNAL OF MEDICAL ECONOMICS, 2022, 25 (01) : 182 - 192